
Conversio HEALTH

Chronic Respiratory Condition Management



COPD Facts & Treatment Challenges

- COPD prevalence rate of 15% in Medicare Advantage¹
- Respiratory is 3rd highest spend category for Part D program
- 2x higher annual medical costs compared to avg. Medicare beneficiary (\$28,828 vs. \$13,872 per year)
- \$29,000+ average COPD hospitalization cost; \$2,100+ average COPD ED cost⁴
- COPD exacerbations account for 50%-75% of total annual cost high % of avoidable cost!





High Medication Copays

94% of patients with incomes under \$25k stated they **did not fill prescriptions due to the high costs**²



Poor Inhaler Technique 85% of COPD patients use inhalers ineffectively, leading to an inadequate dose being delivered to the lungs⁸



Suboptimal Prescribing Patterns

71% of moderate-to-severe COPD patients are not prescribed maintenance drug therapies consistent with GOLD guidelines⁸

Low Medication Adherence

33% avg. medication adherence³ → Non-adherent patients have a 58% higher risk of hospitalization



Limited Nebulizer Medications While nebulizers can help patients overcome challenges with inhalers, le

overcome challenges with inhalers, longacting combination medications are currently only available in inhaler form



Lack of Patient Education

Only **35%** of patients **are knowledgeable about COPD medications** and only **27%** are aware of how to recognize and prevent an exacerbation⁶


1. https://bit.ly/31q1qqd 2. https://bit.ly/31q1qqd 2. https://www.sciencedirect.com/science/article/pii/S0954611117301737.8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2629978/. 9 https://www.ncbi.nlm.nih.gov/pmc/articl





THE ASTHMA OPPORTUNITY

Asthma affects **1 in 13** people in the country and costs over **\$80 Billion** annually to the US economy due to hospitalizations, poor patient education, environmental conditions.



High intensity treatment

= needs high dose LABA/ICS or medium dose (LABA/ICS + OCS)

Difficult-to-treat asthma

high intensity treatmenthave poor symptom control

Severe Asthma

- = high intensity treatment
- + have poor symptom control

+ need additional guidance with adherence and inhaler technique

\$12K

average annual total cost of care for high-risk asthma patients

62%

of asthma patients in the US annually experience uncontrolled asthma symptoms

30%

of asthma patients do not have asthma action plans

2X

Likely for pediatric patients to have asthma-related hospitalizations

Who is Conversio Health?

• Conversio Health is a **healthcare services provider** that works with health plans and riskbearing providers to help **manage high and rising risk COPD and Asthma** patients

What does Conversio Health do?

- Home delivery of respiratory medications and devices:
 - Unique combination-ingredient nebulizer medications with no patient copay
 - Inhalers and inhaler spacers
 - Compressor nebulizers, Smart & Portable Nebulizers, Inhaler sensors + Spirometers
 - Fast and Free Shipping (even overnight!)
- High-touch condition and pharmacotherapy management services:
 - Clinical Pharmacists, Respiratory Therapists and Health Coaches on staff
 - Provide recurring patient education, support, and coordination
 - Clinical monitoring
 - Proactive clinical interventions upon increases in exacerbation risk/deviations in clinical baselines
 - Virtual Pulmonary Rehabilitation Program
 - Exercises, breathing techniques, educational content, COPD Action Plans, smoking cessation support + 1:1 weekly consultations

Conversio Payor/Provider Partners in OR:



COPD

COPD/Asthma Program Goals:

- ✓ Improve COPD/Asthma medication therapy
 - Help get patients on optimal respiratory medication therapy based on evidence-based prescribing guidelines, improve lung deposition
- Improve COPD/Asthma control medication adherence
 - Medication affordability, patient education, remote patient monitoring
- Reduce avoidable ED and hospital utilization
- ✓ Increase satisfaction and quality of life
 - By providing a personalized program, tools, and support to help patients, providers, and caregivers better manage their respiratory condition



COPD and/or Asthma

COPD & Asthma Management Program Overview



Predictive Analytics & Risk Stratification Algorithms

- Identifies patients at heightened risk of exacerbation and generates actionable alerts
- Identifies potential suboptimal medication therapy relative to GOLD/GINA guidelines

Asthma / COPD Pharmacy Fulfillment

- Unique long-acting combination nebulizer medications which can help patients that struggle to use inhalers properly (e.g., hand-breath coordination and/or low inspiratory flow) – no copay!
- Inhalers for patients who prefer them across all drug classes
- Nebulizers (compressor and smart/portable), inhaler sensors + spirometers


High-Touch Condition and Pharmacotherapy Management Services:

- Routine education and touchpoints with Clinical Pharmacists, RTs, and Health Coaches
- Recurring COPD Assessment Tests / Asthma Control Tests
- Ongoing medication adherence and effectiveness monitoring
- Proactive clinical interventions to prevent and control exacerbations
- Inspire[™] Virtual Pulmonary Rehabilitation program for COPD patients
- Coordination with providers to adjust medication therapy as disease progresses




Convenient, Fast, and Free Shipping Directly to Patients' Homes

No cost to patient, provider, or payer (even for overnight shipping!)







Conversio Nebulizer Medication Portfolio

 \checkmark



Nebulized medication options available in every therapeutic class

85% of patients make critical errors using inhalers, leading to an inadequate dose being delivered to the lungs



No member cost-share removes financial barrier to medication adherence

94% of patients with incomes under \$25k stated they did not fill prescriptions due to the high costs

	Conversio Nebulizer Medications	Inhaler Medications Available	Nebulizer Medications Available
SABA/SAMA	Albuterol / Ipratropium (3 strengths)	Combivent	Duoneb
SABA/ICS	Albuterol 2.5mg / Budesonide 0.5mg	Airsupra	NONE
ICS	Budesonide 0.4mg	Pulmicort, Qvar, Flovent, Arnuity	Budesonide
LAMA	Glycopyrrolate 75mcg	Spiriva, Tudorza, Incruse	Yupelri
LABA/ICS	Formoterol 12mcg / Budesonide 0.5mg	Advair, Breo, Symbicort, Dulera	NONE
LABA/LAMA	Formoterol 12mcg / Glycopyrrolate 37.5mcg	Bevespi, Anoro, Stiolto	NONE
LABA/LAMA/ICS	Formoterol 12mcg / Glycopyrrolate 37.5mcg / Budesonide 0.5mg	Trelegy, Breztri	NONE

SAFETY & QUALITY

 \checkmark Over a decade long history \rightarrow 30+ million doses produced with no serious adverse events

- ✓ All ingredients are USP-Grade and components of FDA approved drugs
 - All formulations are tested by 3rd party FDA-registered lab to validate stability over 180-day period

Conversio Health's Smart Devices

SmartNeb[®] Portable Nebulizer



HEALTH

WIRELESS

Automatic data sync via Bluetooth to Conversio Connect App

Real-time adherence data recorded via onboard storage

PORTABLE

Pocket-sized — 2" x 2.9" x 4.4"

Rechargeable lithium battery (4+ hours of continuous nebulization)

OPTIMIZED

Ultrafine particles for optimized lung deposition: 80% < 5µm

Smart sensor detects breathing to optimize medication delivery

SmartCap[®] 3-in-1 Inhaler Device

SMART SENSOR

Records inhaler medication adherence in real-time

Records inhaler technique data (hand-breath coordination, orientation)

CLINICAL-GRADE SPIROMETER

Captures FEV1 and PEF spirometry readings – from the same device

At-home spirometry in < 10 seconds

TRAINING DEVICE

Light and audio queues train and encourage proper inhaler technique


Onboard storage allows comparison to personal best and average






1:1 Weekly/Monthly Sessions

Between patients and Conversio Health Coaches, RTs, and Clinical Pharmacists






Impact of Virtual Pulmonary Rehab

- Lower 30-day all-cause readmissions
- Improved quality of life, significant reductions in total cost of care
- Shown to be equally impactful as traditional pulmonary rehab
- · Higher engagement due to less barriers and greater convenience

8



Conversio staff average **13+** *touchpoints per year with each patient*






Patient Enrollment

Conversio works with partners to maximize frictionless enrollment

Conversio Enrollment Channels



<section-header><section-header><section-header><section-header><section-header><section-header><complex-block><section-header><complex-block>

- Co-Branded brochures can be mailed to patients meeting the agreed-upon "Target" criteria
- Caregivers, providers, or patients themselves can enroll through Signup.Conversiohealth.com
- Conversio's Enrollment Team can call target patient population to invite and assist with enrollment

Referral Pathways



- Conversio provides monthly patient target lists, so providers know which patients to refer to Conversio
- Conversio participates in periodic recurring provider education sessions with client to socialize program benefits and review progress
- Client's Care Management and Pharmacy teams can refer patients to Conversio (e.g., post hospital discharge, during MTM calls, etc.)

Enrolling your patients with Conversio Health

Conversio Partners in OR:





UMPQUA HEALTH

E-Prescribe via EHR


Search for "Conversio Health" located at:

720 Aerovista Pl San Luis Obispo, CA 93401

- Destination -	Force to Fax
Destination:	CONVERSIO HEALTH V
	Patient's Primary Default Pharmacy
Address:	720 AEROVISTA PLACE STE A
City:	SAN LUIS OBISPO
State:	CA Zip: 93401
Phone:	(866) 239-3784
Fax:	(800) 977-9255
	1
Preview Rx	

Fax or Email

Fax a prescription to 1-800-977-9255 or send a secure email to referrals@conversiohealth.com





Providers can also call in a prescription to Conversio Health at 1-866-239-3784:



Any questions or issues? Call us at 866-239-3784 or email info@conversiohealth.com!

Thank you.

LEARN MORE ABOUT CONVERSIO HEALTH →

Conversio Health Contact Information:

- Toll-Free number : 1-866-239-3784
- Website : <u>www.conversiohealth.com</u>
- Email : info@conversiohealth.com
- Fax: 1-800-977-9255

Summary of Benefits

- ✓ Improve COPD/Asthma medication therapy & adherence
- ✓ Reduce avoidable ED and hospital utilization
- ✓ Financial savings for at-risk providers and patients
- Save time by utilizing Conversio's personalized program, tools, and support that help patients, providers, and caregivers better manage patients' respiratory condition

Conversio Health Asthma Program

Asthma Medication Fulfillment		Tech-Enabled Asthma Management				
Nebulizer Medications		SmartNeb Portable Nebulizer	SmartCap Inhaler Sensor + Spirometer	Conversio Connect App	High-Touch Services	
Frequent Asthma Drug Classes	Conversio Nebulizer Formulations			Key Key All All All Codd All Codd </th <th rowspan="4"></th>		
SABA/ICS	Albuterol 2.5mg / Budesonide 0.5mg					
LABA/ICS	Formoterol 12mcg / Budesonide 0.5mg					
LABA/LAMA/ ICS	Formoterol 12mcg / Glycopyrrolate 37.5mcg / Budesonide 0.5mg	Conversio				
Commercial Inhaler Medications (+ Spacers)		 Enables conversion to nebulizer medications for patients who can't use 	 Rescue inhaler utilization monitoring Records inhaler technique 	 Air quality/weather alerts for allergy-induced asthmatics Tailored educational content 	 Recurring education and check-in calls from Conversio Care Team 	
SymbicortDuleraBreo	AdvairTrelegy BreztriAirsupra	 inhalers properly (e.g., pediatric and elderly asthmatics) Records adherence Portable and convenient 	 data and coaches patients on correct technique via visual and audio queues Doubles as a clinical-grade spirometer (records FEV₁ and 	 Gamification to encourage behavior change Health status assessments and more! 	 Asthma Action Plans Smoking Cessation support Medication therapy optimization 	
CONFIDENTIAL — PLEASE DO NOT COPY OR FORWARD			PEF)		 Proactive interventions 13 	

Significant improvement in clinical outcomes and total cost of care

Study Design

Integrated delivery system recently completed an internal health economics study on their **2,697 high and rising risk COPD** patients that were enrolled with Conversio in 2022.

The study compared total cost of care in CY 2022 between:

- 1. 2,697 high-risk COPD patients that were enrolled with Conversio Health
- 2. A cohort of similar COPD patients that were not enrolled with Conversio Health

Clinical Results

- COPD med. adherence improved from 43% to 78% (81% improvement)
- 27% reduction in all-cause hospital admits per K
- 37% reduction in all-cause hospital bed days per K
- **17%** reduction in all-cause readmissions
- **27%** reduction in all-cause emergency department visits per K

